RxDoctor Payments Data

Athena Friese, MD

Family Medicine · Yukon, OKNPI 1487600086

Payments from drug & device makers

$8,796in general payments, 2019–2025

Across 629 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Pfizer$954
  • Lilly USA, LLC$886
  • AbbVie$800
  • GSK$720
  • Novo Nordisk$666
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,17599%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,796 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$101,105
Medicare patients
240
Services billed
1,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$135,271
OzempicSemaglutide70$93,664
JardianceEmpagliflozin48$74,142
TrulicityDulaglutide40$64,112
EliquisApixaban70$63,913
TradjentaLinagliptin18$25,871
Repatha SureclickEvolocumab19$23,170
RybelsusSemaglutide17$22,240
XareltoRivaroxaban28$21,523
ProliaDenosumab11$18,577
Soliqua 100-33Insulin Glargine/Lixisenatide15$18,501
FarxigaDapagliflozin Propanediol12$18,473
VraylarCariprazine Hcl11$15,122
Tresiba Flextouch U-200Insulin Degludec24$13,639
Spiriva HandihalerTiotropium Bromide15$11,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$886$199,382131 claims
Novo NordiskOzempic, Rybelsus$666$115,90387 claims
Boehringer IngelheimJardiance, Tradjenta$1,171$100,01266 claims
PfizerEliquis$954$63,91370 claims
Johnson & JohnsonXarelto$144$21,52328 claims
AmgenProlia$384$18,57711 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$189$18,50115 claims
AstraZenecaFarxiga$282$18,47312 claims
AbbVieVraylar, Synthroid$800$17,67043 claims
Astellas Pharma US IncMyrbetriq$407$10,85517 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$4,990408 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →